This Week’s Biopharma News: Amgen Deepens US Manufacturing Push - Summary - MDSpire
Feature

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min

Share

Pfizer's ELREXFIO showed significant improvement in progression-free survival (PFS) for multiple myeloma patients in a Phase 3 trial. This study achieved its primary endpoint compared to the standard treatment of daratumumab, pomalidomide, and dexamethasone. Viridian’s elegrobart also demonstrated positive results in treating chronic thyroid eye disease. Additionally, Johnson & Johnson's JNJ-4804 showed efficacy in refractory inflammatory bowel disease, while Avalo's abdakibart was effective for hidradenitis suppurativa. Other updates include FDA actions on daraxonrasib for pancreatic cancer and Australian approval for NIKTIMVO in graft-versus-host disease.

Original Source(s)

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

  • May 12, 2026

Related Content

Roswell Park Study: Inhibiting Regulator Protein Can Make Aggressive Prostate Cancers More Vulnerable

Team shows BCL-2 promotes treatment resistance, uncovering strategy for making tumors respond to treatment.

  • by

  • May 11, 2026

  • 4 min
New Research Sheds Light on How Precancerous Lesions Form in the Pancreas

Discoveries about two metabolic enzymes could point the way to biomarkers, opportunities to prevent cancer.

  • by

  • May 11, 2026

  • 3 min
Roswell Park Experts Highlight Untapped Potential of CDK Inhibitor Cancer Therapy

Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which slow or stop the uncontrolled multiplication of cancer cells.

  • by

  • May 11, 2026

  • 3 min